Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LPM3770164 Sustained-release Tablets in Healthy Subjects
NCT06216054Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in tardive dyskinesia (TD) and Huntington disease (HD) comparing LPM3770164 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse event. Started Dec 2023; status: completed.
02
Drugs
LPM3770164
03
Conditions
tardive dyskinesia (TD)Huntington disease (HD)
Beyond the preview
Go deeper on NCT06216054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216054.